| Shuang Zhang,Jingjing Liu,Hui Li,Ying Cheng. Anti-angiogenesis in lung cancer therapy: the shore and the other shore. Oncol Transl Med, 2015, 1: 15-19. |
| Anti-angiogenesis in lung cancer therapy: the shore and the other shore |
| Received:December 31, 2014 Revised:February 02, 2015 |
| View Full Text View/Add Comment Download reader |
| KeyWord:angiogenesis; non-small cell lung cancer (NSCLC) |
| Author Name | Affiliation | E-mail | | Shuang Zhang | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | zhangshuangphy@126.com | | Jingjing Liu | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | jingjingstone@126.com | | Hui Li | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | zhangshuangphy@126.com | | Ying Cheng* | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | jl.cheng@163.com |
|
| Hits: 8698 |
| Download times: 11326 |
| Abstract: |
| Angiogenesis is known to be an important event in tumor growth. In preclinical and clinical researches, anti-angiogenesis therapy has made great progress, but there are still many problems for future anti-angiogenesis therapy. Here, we review recently completed clinical trials of emerging antiangiogenic agents in patients with non-small cell lung cancer (NSCLC) and discuss the challenges of anti-angiogenic therapy. |
| Close |
|
|
|